 |
市场调查报告书
商品编码
1983289
骨髓发育不良症候群治疗市场：依药物、给药途径、通路及地区划分Myelodysplastic Syndrome Treatment Market, By Drug, By Route Of Administration, By Distribution Channel, By Geography |
||||||
2026年骨髓发育不良症候群治疗市场规模估计为29.9亿美元，预计到2033年将达到46.3亿美元。预计2026年至2033年，该市场将以6.4%的复合年增长率成长。
| 分析范围 | 分析详情 | ||
|---|---|---|---|
| 基准年 | 2025 | 市场规模（2026 年） | 29.9亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2026-2033 |
| 预测期（2026-2033 年）复合年增长率 | 6.40% | 预计金额（2033 年） | 46.3亿美元 |
骨髓发育不良症候群)是一组癌症，其特征是骨髓中未成熟的血球无法成熟并分化为正常血球。不同类型的骨髓发育不良症候群是根据血球和骨髓的特定变化进行诊断的。骨髓发育不良症候群(MDS) 是一种罕见的癌症，其特征是正常血球生成不足。它也被称为骨髓增生异常综合症。 MDS 有多种类型。在 MDS 中，骨髓中的一些细胞异常（发育不良），难以产生新的血球。这些骨髓细胞形成的一些血球有缺陷。这些缺陷细胞通常比正常细胞死亡得更快，而且身体还会破坏一些异常血细胞，因此患者体内剩余的正常血球不足。虽然多种类型的细胞都可能受到影响，但骨髓发育不良症候群最常见的观察是红血球缺乏（贫血）。治疗相关性 MDS 是骨髓发育不良症候群的一种类型。这是由于既往癌症治疗中的化疗或放射线治疗所致。在美国，骨髓发育不良症候群的新病例和治疗相关性骨髓发育不良症候群的病例都在增加。这主要是由于人口老化程度的提高以及癌症治疗后生存期的延长。
市场动态
Azacitidine在北美、拉丁美洲、欧洲、亚太和非洲等主要地区的上市和核准不断增加，预计将在预测期内推动骨髓骨髓发育不良症候群治疗市场中Azacitidine细分市场的成长。例如，2018年2月，生技公司百济神州宣布在中国推出维达兹（Azacitidine注射液）。维达兹已在中国获准用于治疗中危险/高风险第2型骨髓发育不良症候群（MDS）、急性骨髓性白血病（AML）以及慢性粒单核细胞白血病（CMML）。该产品由百济神州在中国核准，并获得新基公司（一家製药公司）的独家授权。
本报告的主要特点
- 本报告指出了各个细分市场的潜在商机，并概述了该市场中一系列有吸引力的投资提案。
- 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本文根据以下参数，介绍了全球骨髓发育不良症候群(MDS) 治疗市场主要企业的概况：公司概况、产品系列、主要亮点、财务绩效和策略。
- 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
- 《全球骨髓发育不良症候群(MDS) 治疗市场》报告面向该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员可以透过分析全球骨髓发育不良症候群(MDS) 治疗市场中使用的各种策略矩阵来促进决策。
目录
第一章：分析目标与假设
- 分析目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章：市场动态、监管与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 法规环境
- 产品上市及核准
- PEST分析
- 波特的分析
- 市场机会
- 法规环境
- 主要进展
- 产业趋势
第四章：全球骨髓发育不良症候群治疗市场：按药物划分（2020-2033 年）
- Lenalidomide
- Decitabine
- Azacitidine
- 处于 III 期临床实验阶段的药物
第五章：全球骨髓发育不良症候群治疗市场：依给药途径划分（2020-2033 年）
- 注射
- 口服
第六章：全球骨髓发育不良症候群治疗市场：依通路划分（2020-2033 年）
- 医院药房
- 零售药房
- 网路药房
第七章 全球骨髓发育不良症候群治疗市场：按地区划分（2020-2033 年）
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
- 非洲
- 南非
- 北非
- 中非
第八章 竞争情势
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
第九章 分析师建议
- 机会
- 分析师意见
- Coherent Opportunity Map (COM)
第十章：参考文献与分析方法
- 参考
- 分析方法
- 关于 Coherent Market Insights
Myelodysplastic Syndrome Treatment Market is estimated to be valued at USD 2.99 Bn in 2026 and is expected to reach USD 4.63 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.99 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.40% | 2033 Value Projection: | USD 4.63 Bn |
Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer.
Market Dynamics
Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company).
Key features of the study
- This report provides an in-depth analysis of the global myelodysplastic syndrome (MDS) treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myelodysplastic syndrome (MDS) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myelodysplastic syndrome (MDS) treatment market
Market Segmentation
- Drug Insights (Revenue, USD Bn, 2026 - 2033)
- Lenalidomide
- Decitabine
- Azacitidine
- Phase 3 Drugs
- Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
- Injection
- Oral
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Myelodysplastic Syndrome Treatment Market, By Drug
- Global Myelodysplastic Syndrome Treatment Market, By Route of Administration
- Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel
- Global Myelodysplastic Syndrome Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Myelodysplastic Syndrome Treatment Market, By Drug, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Lenalidomide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Decitabine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Azacitidine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Phase 3 Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
5. Global Myelodysplastic Syndrome Treatment Market, By Route of Administration, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
7. Global Myelodysplastic Syndrome Treatment Market, By Region, 2020 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acceleron Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aprea Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FibroGen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Onconova Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Geron
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
